Annovis Bio, Inc. (ANVS) Stock Analysis & Investment Frameworks
Annovis Bio, Inc. (ANVS) stock analysis on Invetso. Review Annovis Bio, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Annovis Bio, Inc. Company Overview
- Exchange: New York Stock Exchange
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Annovis Bio, Inc. Key Financial Metrics
- Market Cap: $36.06M
- Revenue: $N/A
- ROE: -685.96%
- ROIC: -400.40%
- Dividend Yield: N/A
About Annovis Bio, Inc.
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions. Beyond Buntanetap, Annovis Bio is developing ANVS405 to offer protection against traumatic brain injury and stroke. Additionally, ANVS301 is progressing through Phase I clinical trials, aiming to enhance cognitive capabilities in the later stages of Alzheimer's disease and broader dementia. The company was founded in 2008 and operates out of Berwyn, Pennsylvania.
Annovis Bio, Inc. Investment Frameworks
Invetso analyzes Annovis Bio, Inc. (ANVS) across the following frameworks:
- Annovis Bio, Inc. 10Y Growth Potential
- Annovis Bio, Inc. Scenario Analysis
- Annovis Bio, Inc. Risks & Opportunities
- Annovis Bio, Inc. Economic Moat
- Annovis Bio, Inc. Business Model
- Annovis Bio, Inc. Management
- Annovis Bio, Inc. SWOT Analysis
- Annovis Bio, Inc. Porter's 5 Forces
- Annovis Bio, Inc. PESTLE Analysis
- Annovis Bio, Inc. ESG Analysis